In response to their continued growth in the in-vitro diagnostics market, Diatron, a global provider of hematology and clinical chemistry analyzers, has moved to new, larger modern facilities in Budapest, Hungary. The move enables Diatron to consolidate their production and support of their clinical chemistry and hematology analyzers onto one site.
The news follows the recent US Food and Drug Administration (FDA) approval of two of the company's hematology analyzers, the Abacus 3CP, 3-part differential analyzer and Abacus 5, 5-part differential analyzer.
With more than 30,000 hematology analyzers already sold in over 100 international markets, the creation of the new production facilities, together with the US FDA approvals, are important milestones that have strengthened Diatron's global position, opening up many additional opportunities in the US market.
According to Ronald Backes, Vice President of International Business Development at Diatron, "One of the outcomes of the new production facility will be to concentrate our research and design efforts. This will allow us to ensure we are producing analyzers that match our customer's needs and provide an optimum service in terms of reliability, efficiency and cost-effectiveness".